Početna › Limfom › Massachusetts › Boston
Kliničke studije za Limfom u gradu Boston, MA
33 studija za Limfom traži sudionike na lokacijama u gradu Boston i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
U tijeku regrutacijaFaza 2
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
U tijeku regrutacija
- Mass General Hospital, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
U tijeku regrutacija
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
U tijeku regrutacijaFaza 1/2
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
U tijeku regrutacijaFaza 2
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
U tijeku regrutacijaFaza 1/2
- Research Site, Boston
- Research Site, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
U tijeku regrutacijaFaza 1/2
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
U tijeku regrutacijaFaza 3
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
U tijeku regrutacijaFaza 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
U tijeku regrutacijaFaza 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
U tijeku regrutacijaFaza 2
- Dana Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
U tijeku regrutacijaFaza 1/2
- Call for Information (Investigational Site 0026), Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
U tijeku regrutacijaFaza 1/2
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
U tijeku regrutacijaOpažajna studija
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
U tijeku regrutacija
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
U tijeku regrutacija
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
U tijeku regrutacijaFaza 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
U tijeku regrutacija
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
U tijeku regrutacijaFaza 2
- Dana-Farber Cancer Institute, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
U tijeku regrutacijaFaza 2
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
U tijeku regrutacijaFaza 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
U tijeku regrutacijaFaza 2
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
U tijeku regrutacijaFaza 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
U tijeku regrutacijaFaza 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
U tijeku regrutacijaFaza 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
U tijeku regrutacija
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
U tijeku regrutacijaFaza 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
U tijeku regrutacijaFaza 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
U tijeku regrutacijaFaza 2
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
U tijeku regrutacija
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Studije za Limfom u drugim gradovima
- Houston, TX34 studija
- New York City, NY33 studija
- Washington, DC23 studija
- Baldwin Park, CA21 studija
- Chicago, IL20 studija
- Durham, NC17 studija
- St. Louis, MO15 studija
- Philadelphia, PA15 studija
- Cleveland, OH14 studija
- Edison, NJ12 studija
- Atlanta, GA12 studija
- Seattle, WA12 studija
Ostale studije u gradu Boston
- Rak dojke111 studija
- Nemikrocelularni karcinom pluća90 studija
- Rak (sve vrste)86 studija
- Kolorektalni rak63 studija
- Metastatski karcinom63 studija
- Rak pluća62 studija
- Rak jajnika61 studija
- Rak prostate59 studija
- Depresija52 studija
- Rak endometrija50 studija
- Srčano zatajenje44 studija
- Akutna mijeloična leukemija44 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.